Linked Life Data

2453091

Source:http://linkedlifedata.com/resource/pubmed/id/2453091

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1988-6-23
pubmed:abstractText
Eleven untreated patients with advanced ovarian cancer were studied for tolerance and response to combination treatment with fixed doses of adriamycin (45 mg/m2) and cyclophosphamide (600 mg/m2) + escalating doses of carboplatin. At the first dose level of carboplatin (200 mg/m2), toxicity was acceptable. With carboplatin at 300 mg/m2, severe hematologic toxicity was observed. The dose-limiting toxicity was leukopenia. Although carboplatin was administered without any hydration, no patient experienced renal toxicity. Eight objective responses were observed in 9 clinically evaluable patients. At second look surgery, 3 complete responses and 4 partial responses were documented. Polychemotherapy with JAC (carboplatin, 200 mg/m2, adriamycin, 45 mg/m2, and cyclophosphamide, 600 mg/m2) is administrable with acceptable toxicity.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0300-8916
pubmed:author
pubmed:issnType
Print
pubmed:day
30
pubmed:volume
74
pubmed:owner
NLM
pubmed:authorsComplete
N
pubmed:pagination
217-20
pubmed:dateRevised
2008-12-12
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Carboplatin (JM 8), adriamycin and cyclophosphamide (JAC) in advanced ovarian carcinoma: a pilot study.
pubmed:affiliation
Istituto Nazionale per la Ricerca sul Cancro, Genova.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't